Insider Transactions in Q2 2023 at Athira Pharma, Inc. (ATHA)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 07
2023
|
Andrew Gengos CFO and Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
15,000
+5.81%
|
$45,000
$3.4 P/Share
|
|
Jun 05
2023
|
Andrew Gengos CFO and Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
45,000
+19.22%
|
$135,000
$3.01 P/Share
|
|
Jun 02
2023
|
Hans Moebius Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,882
+8.82%
|
$7,882
$1.35 P/Share
|
|
Jun 02
2023
|
Andrew Gengos CFO and Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
20,012
+31.0%
|
$40,024
$2.85 P/Share
|
|
May 18
2023
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
809
+1.15%
|
$1,618
$2.41 P/Share
|
|
May 18
2023
|
Mark Worthington General Counsel and CCO |
BUY
Grant, award, or other acquisition
|
Direct |
7,767
+22.43%
|
$15,534
$2.41 P/Share
|
|
May 18
2023
|
Hans Moebius Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,764
+9.54%
|
$15,528
$2.41 P/Share
|